BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Farahani M, Niknam Z, Mohammadi Amirabad L, Amiri-Dashatan N, Koushki M, Nemati M, Danesh Pouya F, Rezaei-Tavirani M, Rasmi Y, Tayebi L. Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets. Biomed Pharmacother 2022;145:112420. [PMID: 34801852 DOI: 10.1016/j.biopha.2021.112420] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 22.0] [Reference Citation Analysis]
Number Citing Articles
1 Esteves E, Mendes VM, Manadas B, Lopes R, Bernardino L, Correia MJ, Barros M, Esteves AC, Rosa N. COVID-19 Salivary Protein Profile: Unravelling Molecular Aspects of SARS-CoV-2 Infection. JCM 2022;11:5571. [DOI: 10.3390/jcm11195571] [Reference Citation Analysis]
2 Barilli A, Visigalli R, Ferrari F, Recchia Luciani G, Soli M, Dall’asta V, Rotoli BM. The JAK1/2 Inhibitor Baricitinib Mitigates the Spike-Induced Inflammatory Response of Immune and Endothelial Cells In Vitro. Biomedicines 2022;10:2324. [DOI: 10.3390/biomedicines10092324] [Reference Citation Analysis]
3 Kanapeckaitė A, Mažeikienė A, Geris L, Burokienė N, Cottrell GS, Widera D. Computational pharmacology: New avenues for COVID-19 therapeutics search and better preparedness for future pandemic crises. Biophys Chem 2022;290:106891. [PMID: 36137310 DOI: 10.1016/j.bpc.2022.106891] [Reference Citation Analysis]
4 Majchrzak M, Poręba M. The roles of cellular protease interactions in viral infections and programmed cell death: a lesson learned from the SARS-CoV-2 outbreak and COVID-19 pandemic. Pharmacol Rep 2022. [PMID: 35997950 DOI: 10.1007/s43440-022-00394-9] [Reference Citation Analysis]
5 Khan SA, Lee TKW. Network pharmacology and molecular docking-based investigations of Kochiae Fructus’s active phytomolecules, molecular targets, and pathways in treating COVID-19. Front Microbiol 2022;13:972576. [DOI: 10.3389/fmicb.2022.972576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Beirag N, Kumar C, Madan T, Shamji MH, Bulla R, Mitchell D, Murugaiah V, Neto MM, Temperton N, Idicula-thomas S, Varghese PM, Kishore U. Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation. Front Immunol 2022;13:960733. [DOI: 10.3389/fimmu.2022.960733] [Reference Citation Analysis]
7 Zagaliotis P, Petrou A, Mystridis GA, Geronikaki A, Vizirianakis IS, Walsh TJ. Developing New Treatments for COVID-19 through Dual-Action Antiviral/Anti-Inflammatory Small Molecules and Physiologically Based Pharmacokinetic Modeling. IJMS 2022;23:8006. [DOI: 10.3390/ijms23148006] [Reference Citation Analysis]
8 Rasmi Y, Hatamkhani S, Naderi R, Shokati A, Nayeb Zadeh V, Hosseinzadeh F, Farnamian Y, Jalali L. Molecular signaling pathways, pathophysiological features in various organs, and treatment strategies in SARS-CoV2 infection. Acta Histochem 2022;124:151908. [PMID: 35662001 DOI: 10.1016/j.acthis.2022.151908] [Reference Citation Analysis]
9 Niculae A, Peride I, Nechita A, Petcu LC, Tiglis M, Checherita IA. Epidemiological Characteristics and Mortality Risk Factors Comparison in Dialysis and Non-Dialysis CKD Patients with COVID-19—A Single Center Experience. JPM 2022;12:966. [DOI: 10.3390/jpm12060966] [Reference Citation Analysis]
10 Tamil Selvan M, Gunasekara S, Xiao P, Griffin K, Cowan SR, Narayanan S, Ramachandran A, Hagen DE, Ritchey JW, Rudd JM, Miller CA. SARS CoV-2 (Delta Variant) Infection Kinetics and Immunopathogenesis in Domestic Cats. Viruses 2022;14:1207. [DOI: 10.3390/v14061207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Schön MP. The tick and I: Parasite-host interactions between ticks and humans. J Dtsch Dermatol Ges 2022;20:818-53. [PMID: 35674196 DOI: 10.1111/ddg.14821] [Reference Citation Analysis]
12 Schön MP. Die Zecke und ich: Parasiten-Wirt-Interaktionen zwischen Zecken und Menschen. J Dtsch Dermatol Ges 2022;20:818-55. [PMID: 35711058 DOI: 10.1111/ddg.14821_g] [Reference Citation Analysis]
13 The COVID Tissue Atlas Consortium, Granados AA, Bucher S, Agrawal A, Song H, Chen AT, Peng T, Neff N, Pisco AO, Huang F, Wang B. Comprehensive characterization of the transcriptional response to COVID-19 in multiple organs reveals shared signatures across tissues.. [DOI: 10.1101/2022.05.31.493925] [Reference Citation Analysis]
14 Beirag N, Kumar C, Madan T, Shamji MH, Bulla R, Mitchell D, Murugaiah V, Neto MM, Temperton N, Idicula-thomas S, Varghese PM, Kishore U. Human Surfactant Protein D Facilitates SARS-CoV-2 Pseudotype Binding and Entry in DC-SIGN Expressing Cells, and Downregulates Spike protein Induced Inflammation.. [DOI: 10.1101/2022.05.16.491949] [Reference Citation Analysis]
15 Gudowska-Sawczuk M, Mroczko B. The Role of Nuclear Factor Kappa B (NF-κB) in Development and Treatment of COVID-19: Review. Int J Mol Sci 2022;23:5283. [PMID: 35563673 DOI: 10.3390/ijms23095283] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Tanaka S, Begue F, Veeren B, Tran-Dinh A, Robert T, Tashk P, Lortat-Jacob B, Faille D, de Chaisemartin L, Zappella N, Atchade E, Kramer L, Montravers P, Meilhac O. First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation. Biomedicines 2022;10:754. [PMID: 35453504 DOI: 10.3390/biomedicines10040754] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
17 Barilli A, Visigalli R, Ferrari F, Bianchi MG, Dall’asta V, Rotoli BM. Immune-Mediated Inflammatory Responses of Alveolar Epithelial Cells: Implications for COVID-19 Lung Pathology. Biomedicines 2022;10:618. [DOI: 10.3390/biomedicines10030618] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
18 Jafari A, Danesh Pouya F, Niknam Z, Abdollahpour-Alitappeh M, Rezaei-Tavirani M, Rasmi Y. Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms. Mol Biol Rep 2022. [PMID: 35235159 DOI: 10.1007/s11033-022-07132-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Tirziu A, Paunescu V. Cytotoxic T-Cell-Based Vaccine against SARS-CoV-2: A Hybrid Immunoinformatic Approach. Vaccines 2022;10:218. [DOI: 10.3390/vaccines10020218] [Reference Citation Analysis]
20 Niknam Z, Jafari A, Golchin A, Danesh Pouya F, Nemati M, Rezaei-Tavirani M, Rasmi Y. Potential therapeutic options for COVID-19: an update on current evidence. Eur J Med Res 2022;27:6. [PMID: 35027080 DOI: 10.1186/s40001-021-00626-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]